PRIDE statement on the need for a moratorium on the CMS plan to cite hospitals for performing point-of-care capillary blood glucose monitoring on critically ill patients

David C. Klonoff, Boris Draznin, Andjela T Drincic, Kathleen Dungan, Roma Gianchandani, Silvio E. Inzucchi, James H. Nichols, Mark J. Rice, Jane Jeffrie Seley

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: A writing committee of the Planning Research in Inpatient Diabetes (PRIDE) group has written this consensus article on behalf of the group in response to a specific request for input from the Centers for Medicare and Medicaid Services (CMS). The purpose of this article is to respond to the March 13, 2015 statement from that agency regarding plans to enforce prohibition of the off-label use of point of care (POC) capillary blood glucose monitor (BGM) testing in most critically ill patients. The article discusses: 1) how POC BGM testing is currently regulated; 2) how POC BGM testing is currently used in the United States; and 3) how POC BGM testing can be safely and effectively regulated in the future through cooperation between the clinician, laboratory, regulatory, industry, and patient communities. Participants: Nine members of PRIDE volunteered to write the statement on behalf of the entire group. Evidence: Descriptions of current medical practice for critically ill patients were derived from the experience of the authors. Descriptions of the performance of various methods for measuring glucose levels for intensive insulin therapy came from a literature review. Consensus Process: Eleven questions were developed by the PRIDE writing group. After extensive electronic and telephone discussion, the article was written and reviewed by all nine authors and then reviewed by two outside experts in the care of critically ill patients. All suggestions by the authors and the outside experts were incorporated. Conclusions: Although the CMS is attempting to protect patients with abnormal glycemic control from harm due to inaccurate POC fingerstick capillary BGM testing, their plan will result in more harm than good.Amoratorium on enforcement of the prohibition of off-label use of POC capillary BGM testing is needed.

Original languageEnglish (US)
Pages (from-to)3607-3612
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume100
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Point-of-Care Systems
Centers for Medicare and Medicaid Services (U.S.)
Medical problems
Critical Illness
Blood Glucose
Inpatients
Planning
Monitoring
Testing
Research
Off-Label Use
Labels
Telephone
Industry
Insulin
Glucose

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

PRIDE statement on the need for a moratorium on the CMS plan to cite hospitals for performing point-of-care capillary blood glucose monitoring on critically ill patients. / Klonoff, David C.; Draznin, Boris; Drincic, Andjela T; Dungan, Kathleen; Gianchandani, Roma; Inzucchi, Silvio E.; Nichols, James H.; Rice, Mark J.; Seley, Jane Jeffrie.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 100, No. 10, 01.10.2015, p. 3607-3612.

Research output: Contribution to journalArticle

Klonoff, David C. ; Draznin, Boris ; Drincic, Andjela T ; Dungan, Kathleen ; Gianchandani, Roma ; Inzucchi, Silvio E. ; Nichols, James H. ; Rice, Mark J. ; Seley, Jane Jeffrie. / PRIDE statement on the need for a moratorium on the CMS plan to cite hospitals for performing point-of-care capillary blood glucose monitoring on critically ill patients. In: Journal of Clinical Endocrinology and Metabolism. 2015 ; Vol. 100, No. 10. pp. 3607-3612.
@article{c0b6ec8d09e8491a94aa4087a725e50f,
title = "PRIDE statement on the need for a moratorium on the CMS plan to cite hospitals for performing point-of-care capillary blood glucose monitoring on critically ill patients",
abstract = "Objective: A writing committee of the Planning Research in Inpatient Diabetes (PRIDE) group has written this consensus article on behalf of the group in response to a specific request for input from the Centers for Medicare and Medicaid Services (CMS). The purpose of this article is to respond to the March 13, 2015 statement from that agency regarding plans to enforce prohibition of the off-label use of point of care (POC) capillary blood glucose monitor (BGM) testing in most critically ill patients. The article discusses: 1) how POC BGM testing is currently regulated; 2) how POC BGM testing is currently used in the United States; and 3) how POC BGM testing can be safely and effectively regulated in the future through cooperation between the clinician, laboratory, regulatory, industry, and patient communities. Participants: Nine members of PRIDE volunteered to write the statement on behalf of the entire group. Evidence: Descriptions of current medical practice for critically ill patients were derived from the experience of the authors. Descriptions of the performance of various methods for measuring glucose levels for intensive insulin therapy came from a literature review. Consensus Process: Eleven questions were developed by the PRIDE writing group. After extensive electronic and telephone discussion, the article was written and reviewed by all nine authors and then reviewed by two outside experts in the care of critically ill patients. All suggestions by the authors and the outside experts were incorporated. Conclusions: Although the CMS is attempting to protect patients with abnormal glycemic control from harm due to inaccurate POC fingerstick capillary BGM testing, their plan will result in more harm than good.Amoratorium on enforcement of the prohibition of off-label use of POC capillary BGM testing is needed.",
author = "Klonoff, {David C.} and Boris Draznin and Drincic, {Andjela T} and Kathleen Dungan and Roma Gianchandani and Inzucchi, {Silvio E.} and Nichols, {James H.} and Rice, {Mark J.} and Seley, {Jane Jeffrie}",
year = "2015",
month = "10",
day = "1",
doi = "10.1210/jc.2015-2435",
language = "English (US)",
volume = "100",
pages = "3607--3612",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - PRIDE statement on the need for a moratorium on the CMS plan to cite hospitals for performing point-of-care capillary blood glucose monitoring on critically ill patients

AU - Klonoff, David C.

AU - Draznin, Boris

AU - Drincic, Andjela T

AU - Dungan, Kathleen

AU - Gianchandani, Roma

AU - Inzucchi, Silvio E.

AU - Nichols, James H.

AU - Rice, Mark J.

AU - Seley, Jane Jeffrie

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Objective: A writing committee of the Planning Research in Inpatient Diabetes (PRIDE) group has written this consensus article on behalf of the group in response to a specific request for input from the Centers for Medicare and Medicaid Services (CMS). The purpose of this article is to respond to the March 13, 2015 statement from that agency regarding plans to enforce prohibition of the off-label use of point of care (POC) capillary blood glucose monitor (BGM) testing in most critically ill patients. The article discusses: 1) how POC BGM testing is currently regulated; 2) how POC BGM testing is currently used in the United States; and 3) how POC BGM testing can be safely and effectively regulated in the future through cooperation between the clinician, laboratory, regulatory, industry, and patient communities. Participants: Nine members of PRIDE volunteered to write the statement on behalf of the entire group. Evidence: Descriptions of current medical practice for critically ill patients were derived from the experience of the authors. Descriptions of the performance of various methods for measuring glucose levels for intensive insulin therapy came from a literature review. Consensus Process: Eleven questions were developed by the PRIDE writing group. After extensive electronic and telephone discussion, the article was written and reviewed by all nine authors and then reviewed by two outside experts in the care of critically ill patients. All suggestions by the authors and the outside experts were incorporated. Conclusions: Although the CMS is attempting to protect patients with abnormal glycemic control from harm due to inaccurate POC fingerstick capillary BGM testing, their plan will result in more harm than good.Amoratorium on enforcement of the prohibition of off-label use of POC capillary BGM testing is needed.

AB - Objective: A writing committee of the Planning Research in Inpatient Diabetes (PRIDE) group has written this consensus article on behalf of the group in response to a specific request for input from the Centers for Medicare and Medicaid Services (CMS). The purpose of this article is to respond to the March 13, 2015 statement from that agency regarding plans to enforce prohibition of the off-label use of point of care (POC) capillary blood glucose monitor (BGM) testing in most critically ill patients. The article discusses: 1) how POC BGM testing is currently regulated; 2) how POC BGM testing is currently used in the United States; and 3) how POC BGM testing can be safely and effectively regulated in the future through cooperation between the clinician, laboratory, regulatory, industry, and patient communities. Participants: Nine members of PRIDE volunteered to write the statement on behalf of the entire group. Evidence: Descriptions of current medical practice for critically ill patients were derived from the experience of the authors. Descriptions of the performance of various methods for measuring glucose levels for intensive insulin therapy came from a literature review. Consensus Process: Eleven questions were developed by the PRIDE writing group. After extensive electronic and telephone discussion, the article was written and reviewed by all nine authors and then reviewed by two outside experts in the care of critically ill patients. All suggestions by the authors and the outside experts were incorporated. Conclusions: Although the CMS is attempting to protect patients with abnormal glycemic control from harm due to inaccurate POC fingerstick capillary BGM testing, their plan will result in more harm than good.Amoratorium on enforcement of the prohibition of off-label use of POC capillary BGM testing is needed.

UR - http://www.scopus.com/inward/record.url?scp=84943802581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943802581&partnerID=8YFLogxK

U2 - 10.1210/jc.2015-2435

DO - 10.1210/jc.2015-2435

M3 - Article

C2 - 26398626

AN - SCOPUS:84943802581

VL - 100

SP - 3607

EP - 3612

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 10

ER -